A Study of Combination Therapy in Patients With Resectable Liver Cancer

Inclusion Criteria: * 1\. Voluntarily signed written informed consent. * 2\. Age ≥18 years; male or female. * 3\. Histologically, cytologically, or clinically confirmed hepatocellular carcinoma (HCC) according to EASL/AASLD criteria. * 4\. CNLC stage Ib, IIa, IIb, or IIIa HCC (excluding patients with main portal vein tumor thrombus). * 5\. Presence of vascular invasion and no extrahepatic metastasis, including PVTT (Vp1-Vp3), HVTT, or IVCTT. * 6\. No prior systemic treatment for HCC, including chemotherapy, targeted therapy, or immunotherapy. * 7\. Child-Pugh class A liver function. * 8\. ECOG performance status 0-1. * 9\. Adequate organ function: 1. ANC ≥1.5 × 10\^9/L; Platelet count ≥75 × 10\^9/L; Hemoglobin ≥90 g/L. 2. Albumin ≥30 g/L; Total bilirubin ≤1.5 × ULN; ALT, AST, and ALP ≤5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance \>50 mL/min. 3. INR ≤2.3 or PT prolongation ≤6 seconds. 4. Urine protein \<2+; if ≥2+, 24-hour urine protein \<1.0 g. * 10\. For patients with active HBV infection, effective antiviral therapy is required, with HBV DNA ≤2000 IU/mL or a ≥10-fold reduction after antiviral treatment. * 11\. Women of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during the study and for 6 months after study completion. Male participants must also use effective contraception during the study and for 6 months after study completion. Exclusion Criteria: * 1\. Intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed hepatocellular carcinoma, fibrolamellar carcinoma, or any other active malignancy within the past 5 years (except HCC). * 2\. Severe allergy to iodinated contrast agents that prevents HAIC treatment. * 3\. Planned or prior organ transplantation or allogeneic bone marrow transplantation. * 4\. Treatment with another investigational drug within 28 days before study treatment. * 5\. Current or prior central nervous system metastases. * 6\. History of hepatic encephalopathy. * 7\. Current interstitial pneumonitis or interstitial lung disease. * 8\. Active autoimmune disease or history of autoimmune disease with risk of recurrence. * 9\. Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes within 14 days before study treatment. * 10\. Severe infection within 4 weeks before study treatment. * 11\. Gastrointestinal bleeding within 6 months before study treatment or a known risk of gastrointestinal bleeding. * 12\. Known hereditary or acquired bleeding disorders or thrombotic tendency. * 13\. Uncontrolled clinically significant cardiac disease or symptoms. * 14\. Moderate or severe ascites requiring therapeutic drainage or paracentesis. * 15\. Major vascular disease within 6 months before study treatment. * 16\. Inability to swallow oral medication, malabsorption syndrome, or any condition affecting gastrointestinal absorption. * 17\. Known hypersensitivity to any study drug, its excipients, monoclonal antibodies, or anti-angiogenic agents. * 18\. Any other serious acute or chronic medical condition, psychiatric disorder, or laboratory abnormality that may increase study risk, interfere with study results, or make the patient unsuitable for participation.